MENU
MNOV
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION

Medicinova (MNOV) Ownership - Who owns Medicinova?

MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U... Show more

Industry: #Biotechnology
A.I.Advisor
Nov 12, 2026

What Is MediciNova (MNOV)? Company Overview, Business Model and Market Position

Key Takeaways

  • MediciNova, Inc. (MNOV) is a clinical-stage biopharmaceutical company headquartered in La Jolla, California, founded in 2000.
  • The company develops novel small-molecule therapeutics for serious diseases with significant unmet medical needs, primarily for the U.S. market.
  • Its two lead product candidates are MN-166 (ibudilast) for neurological disorders and MN-001 (tipelukast) for fibrotic and metabolic disorders.
  • MediciNova has no commercially approved products and currently generates minimal revenue, making it a pre-commercialization development-stage company.
  • The stock is listed on the Nasdaq Global Market under MNOV and also trades on the Tokyo Stock Exchange under code 4875.

Introduction

MediciNova, Inc. is a biopharmaceutical company focused on acquiring and developing novel small-molecule therapeutics for diseases that lack adequate treatment options. Rather than discovering drugs from scratch, the company sources and licenses promising clinical-stage and preclinical candidates — often through strategic alliances with Japanese pharmaceutical companies — and advances them through clinical development with an emphasis on the U.S. market. Investors follow MNOV primarily because of its lead neurology program, which targets amyotrophic lateral sclerosis (ALS), a serious and progressive neurodegenerative condition with limited therapies.

Company Profile and Business Model

MediciNova was incorporated in 2000 and is headquartered at 4275 Executive Square, Suite 300, La Jolla, California. The company is led by founder Yuichi Iwaki, who serves as Executive Chairman, President and Chief Executive Officer. MediciNova is a lean organization that manages its international clinical and manufacturing operations through contract research organizations (CROs), which are outside firms that conduct clinical trials on a company's behalf.

The company's business model centers on licensing or otherwise securing rights to drug candidates, then developing those candidates through clinical testing with the goal of obtaining regulatory approval or monetizing them through partnerships and strategic collaborations at key value points. Because MediciNova has not yet received regulatory approval for any product, it does not generate meaningful revenue from product sales. Instead, its financial profile is characteristic of a development-stage biotechnology firm: research and development (R&D) spending, general and administrative expenses, and recurring net losses funded by cash reserves and periodic equity financing.

MediciNova operates as a single reporting segment. Its pipeline is built around two main assets:

  • MN-166 (ibudilast): an oral, anti-inflammatory and neuroprotective agent described by the company as first-in-class. It is being studied for neurological and other disorders including progressive multiple sclerosis (MS), ALS, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS). The U.S. Food and Drug Administration (FDA) has granted Fast Track designation to MN-166 for three separate indications: progressive MS, ALS, and methamphetamine dependence.
  • MN-001 (tipelukast): an orally bioavailable small molecule with anti-inflammatory, anti-fibrotic, and lipid-lowering properties. It is being developed for fibrotic and metabolic disorders such as nonalcoholic fatty liver disease (NAFLD) and hypertriglyceridemia.

Why Investors Follow MNOV

Investor interest in MNOV centers on the potential of its lead candidate, MN-166 (ibudilast), in ALS. ALS is a fatal neurodegenerative disease with few approved treatments, creating a substantial unmet medical need and a significant commercial opportunity if clinical trials succeed. MediciNova has completed enrollment in its Phase 2b/3 COMBAT-ALS trial evaluating MN-166 in ALS patients, a pivotal study whose data readout represents a major milestone for the company.

Beyond ALS, the company's pipeline spans multiple high-value indications across neurology, respiratory, and metabolic disease, providing what management views as a diversified and differentiated portfolio. MN-166 and MN-001 benefit from well-characterized safety profiles accumulated through prior clinical studies, and several programs carry FDA regulatory designations such as Fast Track and Orphan Drug status that can potentially streamline development. MediciNova's capital-efficient model, use of external CROs, and externally funded academic and government collaborations for certain non-core programs also support its market position as a focused, development-stage company.

Risks and Important Considerations

As a clinical-stage biopharmaceutical company, MNOV carries risks typical of the biotechnology sector. The company has no approved products, and its success depends heavily on favorable clinical trial results and subsequent regulatory approval, neither of which is guaranteed. A failure or delay in a key trial such as COMBAT-ALS could materially affect the company's prospects.

MediciNova also faces financing risk. Because it does not generate product revenue, it relies on cash reserves, equity issuances, and potential partnerships to fund operations, and future capital raises may dilute existing shareholders. Its patent estate for the active pharmaceutical ingredients ibudilast and tipelukast relies significantly on method-of-use patents rather than composition-of-matter protection, which can offer less robust defense against generic competition. Other considerations include dependence on third parties for manufacturing and clinical execution, the inherent uncertainty of the regulatory process, and the historical price volatility common to small-cap biotechnology stocks.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery platform that helps traders and investors identify opportunities using technical indicators, fundamentals, volatility, trends, AI-generated signals, industries, price patterns, and customizable filters. Users can efficiently screen thousands of stocks and ETFs to surface ideas that match their own investment strategies. Whether you are researching development-stage biotechs or broader market opportunities, the AI Screener offers a structured way to refine your watchlist.

Conclusion

MediciNova is a focused, development-stage biopharmaceutical company whose investment thesis rests on the clinical progress of its lead candidates, MN-166 and MN-001, across neurological, fibrotic, and metabolic diseases. With a dual listing on Nasdaq and the Tokyo Stock Exchange and a strategy built on licensed assets, strategic partnerships, and a lean operating model, the company remains a closely watched name for investors interested in early-stage drug development and the high-risk, high-reward profile of clinical-stage biotechnology.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations

Profile

Industry
Biotechnology
Address
4275 Executive Square
Phone
+1 858 373-1500
Employees
6
Web
https://www.medicinova.com

Details

Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
71.86M
P/E Ratio
-6.95
Total Cash
25.42M
Projected Growth
N/A
Total Debt
117.04K
Revenue
920.48K
Risk (Beta)
0.99
Dividend Yield
N/A
Total Cash/Share
0.52
Total Debt/Equity
N/A
Revenue/Share
0.02 USD as % of share price
View a ticker or compare two or three
Interact to see
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information

General Information

a biopharmaceutical company, which develops small molecule therapeutics

Industry Biotechnology

Industry
Biotechnology
Address
4275 Executive Square
Phone
+1 858 373-1500
Employees
6
Web
https://www.medicinova.com
Who owns Medicinova? MNOV symbol Ownership - Tickeron.com